Thomas Lehmann

TL;DR: Surprisingly, the number of mutations between early and late patient samples did not significantly change, and during a total follow-up of 133 patient years, only 2 new mutations appeared, suggesting that the mutation rate in MPN is rather low.

TL;DR: The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with demonstrated clinical utility in the largest prospective MPN symptoms study to date.

TL;DR: Findings suggest that, despite the phenotypical difference, the outcome of JAK2 exon 12 mutations-positive PV is similar to that ofJAK2 (V617F)-positive PV.

TL;DR: In 4 of 8 myeloproliferative neoplasm patients, it was found that some colonies with mutated TET2 carried wild-type JAK2, whereas others wereJAK2-V617F positive, indicating that TET1 occurred before JAK1-V615F, and the lack of a strict temporal order of occurrence makes it unlikely that mutations in TET3 represent a predisposing event for acquiring mutations in JAK3.

TL;DR: This data indicates that hematopoietic stem cell transplantation patients after HSCs are at high risk of developing influenza, and the diagnostic methods and antiviral treatment for this disease have scarcely been investigated.